Two phase 1 trials were initiated to study an IgG4 mAb against CD47 in melanoma, which was conjugated to a (not yet fully elucidated) toxin, as a monotherapy and in combination with other immunotherapies including anti-PD-1 (NCT03957096, NCT02890368). The gene discussed is CD47; the disease is melanoma.